The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s, attention deficient hyperactivity, Huntington’s disease, Parkinson’s disease and schizophrenia.
Suven has three European patents granted until now and all of them have been validated in all the 37 member countries of Europe.
Venkat Jasti, CEO of Suven, said: “We continue to work on G-Protein coupled receptor targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential.”